search-toggle
backspace

T2 could save lives – bottomline.

  • Get patients on the right therapy faster
  • Improve morbidity and mortality outcomes
  • Reduce costs
  • Improve antimicrobial stewardship

Life

Learn More

Now, hospitals can detect and identify sepsis-causing pathogens faster and more accurately.

Hospitals trust in T2 technology.

UPMC

Demonstrated

47%

reduction in antifungal therapy.

Learn More

Henry Ford Health System

Realized

7 days

reduction in median length of stay in the ICU.

Learn More

Lee Health

T2Bacteria positive results

20 hours

sooner than blood culture.

Learn More

Huntsville Hospital

Saved

~$280

pharmacy costs per patient.

Learn More

Robert Wood Johnson Medical School

Identified escalation and
de-escalation opportunities in patients tested with T2Candida.

Learn More

Riverside Community Hospital 

100%

of patients who tested positive received appropriate therapy in <9 hours

Learn More

Hospitals trust in T2 technology.

Gregorio Marañón Hospital in Madrid, Spain

Two 2018 studies 

from Gregorio Marañón Hospital in Madrid, Spain.

Learn More

Rigshospitalet, Denmark

"T2Candida was superior to blood culture and mannan antigen and may improve diagnosis." Learn More

Gemelli Hospital, Italy

66.7%

of the clinically infected patients missed by blood culture were correctly identified by T2Bacteria Learn More

La Paz Hospital University, Spain

T2Candia Panel

contributed to the healthy discharge of a 1-year-old transplant patient. Learn More

Patient Case Studies

Real stories about how T2Direct Diagnostics™ could have potentially changed clinical practice and patient outcomes.

Case Study 1

53-year-old immunocompromised, female with recent surgery to drain an intra-abdominal abscess
Read Case Study

Case Study 2

25-year-old female with cerebral palsy diagnosed with duodenal pneumatosis
Read Case Study

Case Study 3

73-year-old female with lymphoma on chemotherapy and diagnosed with pneumonia and septic shock
Read Case Study

Case Study 4

84-year-old male with diabetes, prostate cancer and end stage renal disease on hemodialysis
Read Case Study

Patient case studies

Real stories about how T2Direct Diagnostics™ could have potentially changed clinical practice and patient outcomes.

Case Study 1

53-year-old immunocompromised, female with recent surgery to drain an intra-abdominal abscess
Read Case Study

Case Study 2

25-year-old female with cerebral palsy diagnosed with duodenal pneumatosis
Read Case Study

Case Study 3

73-year-old female with lymphoma on chemotherapy and diagnosed with pneumonia and septic shock
Read Case Study

Case Study 4

84-year-old male with diabetes, prostate cancer and end stage renal disease on hemodialysis
Read Case Study

Numbers don't lie.

cost-savings

Cost of sepsis

$27 billion in US healthcare costs

Sepsis kills

~6 million people worldwide annually.

Sepsis contributes to

1 in 2-3 US hospital deaths.
Integrate T2Direct Diagnostics into your hospital today!
Learn More
Nature

19th-Century diagnostic methods make it too easy for “ESKAPE” pathogens to escape

In 2004, microbiologist Carl Nathan, M.D., wrote in a Nature commentary that: "Treating infections with pathogen-specific rather t...More
Read Article View Blog

T2 Biosystems OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. "T2Biosystems" and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, and T2Plex™ are trademarks of T2 Biosystems, Inc.

© 2019 T2 Biosystems, Inc.

Join in on Twitter

Sitemap

 

Follow Us on Social

Please tell us where you are visiting from

T2Direct Diagnostics™ may be available in your area. Please contact info@t2biosystems.com for more detailed information about availability in your area.